Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BFRI

BFRI - Biofrontera Inc. Stock Price, Fair Value and News

$0.97-0.01 (-1.02%)
Market Closed

50/100

BFRI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

50/100

BFRI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.05

Target 3M

$1.01

Target 6M

$1.03

BFRI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BFRI Price Action

Last 7 days

-3%

Last 30 days

32.9%

Last 90 days

-9.3%

Trailing 12 Months

-8.5%

BFRI RSI Chart

BFRI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BFRI Valuation

Market Cap

11.3M

Price/Earnings (Trailing)

-0.64

Price/Sales (Trailing)

0.3

EV/EBITDA

-0.48

Price/Free Cashflow

-0.94

BFRI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.05

Target 3M

$1.01

Target 6M

$1.03

BFRI Fundamentals

BFRI Revenue

Revenue (TTM)

37.3M

BFRI Earnings

Earnings (TTM)

-17.6M

Earnings Growth (Yr)

-17.29%

Earnings Growth (Qtr)

-24.89%

BFRI Profitability

EBT Margin

-47.02%

Return on Equity

680.82%

Return on Assets

-113.99%

Free Cashflow Yield

-106.11%

BFRI Investor Care

Shares Dilution (1Y)

50.32%

Diluted EPS (TTM)

-1.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202433.3M34.6M36.0M37.3M
202327.7M29.0M33.6M34.1M
202229.1M27.7M27.7M28.7M
202120.2M21.5M22.8M24.1M
20200022.5M18.8M
201900026.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Biofrontera Inc.

BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.
 CEO
 WEBSITEbiofrontera-us.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES81

Biofrontera Inc. Frequently Asked Questions

BFRI is the stock ticker symbol of Biofrontera Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Biofrontera Inc. is 11.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BFRI's fair value in chart for subscribers.

The fair value guage provides a quick view whether BFRI is over valued or under valued. Whether Biofrontera Inc. is cheap or expensive depends on the assumptions which impact Biofrontera Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BFRI.

As of Wed Jan 28 2026, BFRI's PE ratio (Price to Earnings) is -0.64 and Price to Sales (PS) ratio is 0.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BFRI PE ratio will change depending on the future growth rate expectations of investors.